This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Cerivastatin - withdrawal of marketing and distribution (2001)

Authoring team

Cerivastatin was withdrawn from the market in 2001 because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure. The risk was found to be higher among patients who received the full dose (0.8 mg/day) and those who received gemfibrozil concomitantly. Rhabdomyolysis was 10 times more common with cerivastatin than the other five approved statins.

Reference

  1. Bayer plc (9th August 2001). Letter re: Lipobay (cerivastatin) - suspension of marketing and distribution.
  2. Furberg C et al. Withdrawal of cerivastatin from the world market. Curr. Control Trials Cardiovasc Med. 2001 Sep 26;2(5):205–207

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.